Since joining Janssen in 2011, Jami Taylor has worked especially closely with Janssen Diagnostics, helping to lead its efforts to shape the future of its personalized medicine policy for the benefit of patients. Jami is currently co-chair of the Personalized Medicine Diagnostics Working Group at the Biotechnology Industry Organization, chair of the Education Committee of the European Personalized Medicine Association (EPEMED), and the Johnson & Johnson designate to the European Personalized Medicine Association (EPEMED) Board of Directors. Jami is also an active member of the Personalized Medicine Coalition’s Public Policy Committee and of the European Biopharmaceutical Enterprises’ Personalized Medicine Task Force.
Jami joined the Johnson & Johnson Family of Companies after more than 10 years in public affairs consulting where she specialized in alliance development, policy communications, and issue-campaign design and execution. Her experience includes work with the White House Office of Public Liaison, members of the Unites States Congress, and the U.S. Departments of Treasury, Commerce and Health & Human Services to advance legislative priorities on a nationwide scale. Jami is a contributing editor of Global Pharmacovigilance Laws & Regulations: The Essential Reference, a book published by the Food & Drug Law Institute (FDLI) in 2009. She also served as a vice-chair of FDLI’s inaugural conference on U.S. –China Food and Drug Law, held in Beijing in June, 2011. In 2014, Jami was named a Cross-Sector Leadership Fellow of the Presidio Institute, a program sponsored by the White House in support of leaders working to unlock solutions to society's most complex and pressing challenges.